Nexien Biopharma, Inc. Reports Earnings Results for the Full Year Ended June 30, 2020
September 28, 2020 at 11:12 am
Share
Nexien BioPharma, Inc. announced earnings results for the full year ended June 30, 2020. For the full year, the company announced net loss was USD 2.671 million compared to USD 4.300 million a year ago. Basic loss per share from continuing operations was USD 0.05 compared to USD 0.08 a year ago.
Nexien BioPharma, Inc. is engaged in pre-clinical and drug development activities for certain pharmaceutical formulations that include cannabinoids. The Company is focused on developing and commercializing United States Food and Drug Administration (FDA)-compliant cannabinoid pharmaceuticals, drug delivery systems, and related technologies for diseases, disorders and medical conditions. Its flagship research and development programs are focused on advancing formulations that have the potential to improve the treatment outcomes of certain convulsive disorders and neuromuscular disorders, which includes the treatment of myotonic dystrophy. The Company's wholly owned subsidiaries include Intiva BioPharma Inc., NexN Inc. (NexN) and NexDM Inc.